Abstract
The accumulation of redox-active metal ions, in particular copper, in amyloid plaques is considered to the cause of the intensive oxidation damage to the brain of patients with Alzheimers disease (AD). Drug candidates based on a bis(8-aminoquinoline) tetradentate ligand are able to efficiently extract Cu2+ from copper-loaded amyloids (Cu–Aβ). Contrarily, in the presence of a bidentate hydroxyquinoline, such as clioquinol, the copper is not released from Aβ, but remains sequestrated within a Aβ–Cu–clioquinol ternary complex that has been characterized by mass spectrometry. Facile extraction of copper(II) at a low amyloid/ligand ratio is essential for the re-introduction of copper in regular metal circulation in the brain. As, upon reduction, the Cu+ is easily released from the bis(8-aminoquinoline) ligand unable to accommodate CuI, it should be taken by proteins with an affinity for copper. So, the tetradentate bis(8-aminoquinoline) described here might act as a regulator of copper homeostasis.
Keywords: Alzheimers disease, chelating agents, copper homeostasis, medicinal chemistry, therapeutic agents
The pathology of Alzheimers disease (AD) is related to the abnormal deposition of two proteins, amyloid proteins (Aβ) and hyperphosphorylated tau protein, as described by Alzheimer a century ago.[1] The rupture of the homeostasis of two redox-active metal ions, namely copper and iron, in AD brain, and their accumulation in senile plaques has been largely documented.[2], [3]
The strong binding of copper and iron ions with amyloids, their role in the excessive reticulation of Aβ1–42,[4], [5] and in the intense oxidative damage evidenced in AD brain[6,7, 8] have been documented. The catalytic formation of reactive oxygen species (ROS) generated by redox-metal-loaded amyloids, and responsible for Aβ toxicity, has been reported.[9], [10]
In order to decrease the toxicity of Cu–Aβ due to the easy reduction of CuII to CuI under physiological conditions, we designed copper-chelating agents able 1) to retrieve CuII ions from Cu-Aβ, and 2) to transfer these copper ions to regular carrier proteins for regular copper circulation in the brain. Here, we report that bis(8-aminoquinoline) ligands,[11] tetradentate ligands able to chelate CuII with a ligand/metal stoichiometry of 1:1,[12] are able to extract copper(II) at low amyloid/ligand ratios. For comparison, clioquinol (CQ), a bidentate 8-hydroquinoline formerly used as antiprotozoal drug and recently developed as a metal regulator for the treatment of AD,[13] is unable to extract copper ions from Cu–Aβ, but forms a ternary complex Aβ–Cu–CQ. For economic and scientific reasons, we used Aβ1–28 (Figure 1) and Aβ1–16, instead of Aβ1–42. These two short peptides contain the CuII coordination site (Asp1, His6, His13,14) of the N terminus of Aβ peptides, considered to be independent of amyloid length and responsible, at least in part, for ROS production in AD pathology.[14,15,16] In addition, these truncated peptides, behaving as monomers, are likely to be relevant models of longer amyloids.
Figure 1.

Structures of bis(8-aminoquinoline) ligand 1, clioquinol (CQ), and Aβ1–28.
The transfer of copper from Cu–Aβ amyloids to bis(8-aminoquinoline) ligand 1 (Figure 1) was monitored by UV-visible spectrometry, electron spin resonance (ESR) spectroscopy, and mass spectrometry to characterize copper complexes Cu–Aβ and Cu–1.
First, we metalated Aβ1–28 with 1 mol equiv of CuCl2 at room temperature. As previously reported, metalation was instantaneous and proceeded to completion, as evidenced by the decrease by 50 % of the tyrosine-10 fluorescence.[14] The ESR spectrum confirmed the chelation of copper(II) by Aβ (see below). Bis(8-aminoquinoline) ligand 1 was then added (1 mol equiv with respect to Cu–Aβ).
The UV-visible spectrum of the resulting mixture, Cu–Aβ/ligand 1, was superimposable on the spectrum of the complex Cu–1 (λmax=277, 329, 354, 367 nm), indicating that the copper ion was completely extracted from Cu–Aβ and transferred to ligand 1 (Figure 2 a).
Figure 2.

a) Extraction of CuII from Aβ1–28 upon addition of 1, evidenced by UV-visible spectroscopy. Spectrum of Cu–Aβ1–28+1 (Cu–Aβ1–28/1 mol ratio=1:1; —), compared with those of Cu–1 (⋅⋅⋅⋅⋅⋅) and 1 (– – – –); b) Non-extraction of CuII from Aβ1–28 upon addition of clioquinol (CQ), evidenced by UV-visible spectroscopy. Spectrum of Cu–Aβ1–28+CQ (Cu–Aβ1–28/CQ mol ratio=1:2; —), compared with the spectrum of CuCQ2 (⋅⋅⋅⋅⋅⋅). Aβ1–28 and Cu–Aβ1–28 do not significantly absorb in this wavelength range. For experimental details, see the Experimental Section.
By comparison, a similar experiment was carried out with CQ instead of ligand 1. When 2 mol equiv of CQ were added to Cu–Aβ1–28, the resulting UV-visible spectrum exhibited an absorbance at 438 nm (Figure 2 b). This spectrum, significantly different from that of complex Cu(CQ)2 (456 nm, Figure 2 b), was assigned to a ternary Aβ1–28–Cu–CQ complex. A similar ternary complex, but with an 8-hydroxyquinoline analogue of CQ, has been previously reported on the basis of ESR experiments.[17] These data indicated that 2 mol equiv of CQ failed to completely extract CuII from Cu–Aβ. It should be noted that in a different solvent mixture, namely acetonitrile/HEPES buffer (10:90 v/v), bands were broader, and it was not possible to unambiguously distinguish the spectra of Cu(CQ)2 (λmax=450±2 nm) from a putative Aβ–Cu–CQ complex (λmax=446±2 nm).[12]
The fast migration of Cu2+ from Aβ to ligand 1 was confirmed by ESR spectroscopy. The analysis solvent was HEPES buffer (100 mm, pH 7.4) containing 1–3 vol % of DMSO. The spectrum of Cu–Aβ1−16 exhibited an A|| value of 176±3 G with a g|| value of 2.265±0.004 (Figure 3 a). Upon addition of ligand 1 (1 mol equiv; Figure 3 c), the spectrum exhibited an A|| value at 204 G with a g|| value of 2.196±0.002, significantly different from the values for Cu-Aβ1–16. Furthermore, the spectrum was superimposable on the spectrum of Cu–1 in the absence of Aβ (Figure 3 d). In addition, the spectrum of Cu–Aβ1–16 in the presence of 0.5 mol equiv of 1 could be assigned to an equimolecular mixture of Cu-Aβ1–16 and Cu−1 (Figure 3 b). Given these results, it has not been possible to evidence in the process of extracting Cu2+ from Aβ1–28 by 1 any putative copper complex containing both Aβ and 1 as ligands. The hyperfine coupling constants A and g factors are summarized in Table 1.
Figure 3.

Electron spin resonance (ESR) spectra of a) CuII–Aβ1–16, b) CuII–Aβ1–16/1 (1:0.5 mol ratio), c) CuII–Aβ1–16/1 (1:1 mol ratio), d) CuII–1, in HEPES buffer containing 1–3 vol % DMSO.
Table 1.
Electron spin resonance (ESR) parameters for Cu-Aβ, Cu-Aβ-CQ, Cu−1, and Cu(CQ)2.
| A|| [G] | g|| | g⊥ | AN [G] | |
|---|---|---|---|---|
| Cu-Aβ[a] | 176 | 2.265 | 2.053 | n.d.[c] |
| Cu-1[a] | 204 | 2.196 | 2.025 | 13 |
| Cu-Aβ[b] | 114 | 2.408 | 2.079 | n.d.[c] |
| Cu(CQ)2[b] | 157 | 2.311 | 2.064 | n.d.[c] |
| Aβ-Cu-CQ[b] | 193 | 2.225 | 2.069 | n.d.[c] |
In HEPES buffer containing DMSO (1–3 v %)
In DMSO/HEPES buffer (90:10 v/v).
not determined (n.d.)
In addition, for Cu–1, and despite quite broad lines due to the presence of copper ions in natural abundances, the second-derivative spectrum centered on the g⊥ region allowed detection of the super hyperfine structure of copper with an AN value of 13±1 G (Figure 4). The spectrum of Cu–1 exhibited nine lines with relative intensities 1/2/3/2/2/2/3/2/1. This pattern can be assigned to the overlap of two quintuplets with intensities 1/2/3/2/1 due to the complexation of two aniline-type and two quinoline-type nitrogen atoms. This indicates that the complexation of copper by a bis(8-aminoquinoline) evidenced in the solid state by X-ray crystallography[12] was retained in solution. The super hyperfine pattern of Cu–1 was also detectable in the mixture containing Aβ1–16/CuII/1 in a 1:1:1 ratio (Figure 3 c).
Figure 4.

Second-derivative electron spin resonance (ESR) spectrum of CuII−1.
The mixture resulting from addition of CQ in pre-formed Cu–Aβ was analyzed by ESR spectroscopy for comparison. Due to the poor aqueous solubility of CQ and its copper complex Cu(CQ)2,[12b] analyses were performed in DMSO containing 10 vol % of HEPES buffer, pH 7.4.
Note that the spectrum of CuII–Aβ1–16 under these conditions (Figure 5 a) was significantly different than that recorded in HEPES containing only 1–3 vol % of DMSO (Figure 3 a), where A|| was 114 and 176 G, respectively, and g|| was 2.408 and 2.265, respectively (Table 1), indicating that is likely to be involved in the coordination sphere of CuII. When CQ was added to CuII–Aβ1−16 (Cu–Aβ/CQ=1:1 and Cu–Aβ/CQ=1:2; Figure 5 b,c, respectively), the signal of CuII–Aβ1–16 disappeared and a series of resonances different from that of CuII(CQ)2 appeared with an A|| value of 193 G and a g|| value of 2.225, along with that of CuII(CQ)2 (Figure 5 d). This feature suggests that both CQ and Aβ1–16 were acting as ligands of Cu2+.
Figure 5.

Electron spin resonance (ESR) spectra of a) CuII–Aβ1–16, b) CuII–Aβ1–16/CQ (1:1 mol ratio), c) CuII–Aβ1–16/CQ (1:2 mol ratio), d) Cu(CQ)2 in DMSO, containing 10 vol % of HEPES buffer.
The ternary complex Aβ1−16–Cu–CQ was further characterized by mass spectrometry (MS). The Cu–Aβ1−16 complex was first prepared; 1 mol equiv of CQ was then added, and the mixture was immediately analyzed by MS using positive-mode electrospray ionization (ESI+). Along with the peaks corresponding to Aβ1−16 (m/z=978.5, 652.6, 489.7, and 392.0 amu, for z=2, 3, 4, and 5, respectively), a series of multicharged peaks was detected at m/z 1161.9, 774.9, and 581.4 amu with z=2, 3 and 4, respectively (Figure 6 a). This pattern can be assigned to a ternary complex Aβ1–16–Cu–CQ with molecular formula C93H122ClCuIN28O29. The isotopic patterns were consistent with the theoretical profiles (Figure 6 b). The complex Cu–Aβ was also detected at m/z 1008.9, 672.9, 505.0, and 404.2 (z=2, 3, 4, and 5, respectively), indicating that a significant amount of Cu–Aβ was not affected by the presence of CQ (ca. 20 % with respect to free Aβ; for the full-scale spectrum, see Figure S1 in the Supporting Information).
Figure 6.

Electrospray ionization mass spectrum (ESI+-MS) of CuII/Aβ1–16/CQ (1:1:1 mol ratio). a) Experimental spectrum and b) the theoretical pattern for the ternary complex Aβ–Cu–CQ, with molecular formula C93H122ClCuIN28O2.
Under the same conditions, in a mixture containing Cu–Aβ and ligand 1, signals of a putative complex Aβ–Cu–1 were not detected (Figure S2 in the Supporting Information). The major detected compounds were free Aβ and CuII–1 (m/z=421.1 [M−H]+ and m/z=211.1 [M]2+). Only a tiny amount of Cu–Aβ was detected (<4 % with respect to free Aβ), indicating a major demetalation of Aβ.
This result is consistent with the affinity constants of Aβ and the different ligands for CuII. In fact, the apparent log Kaff value of Aβ for CuII was reported to be in the range of 10–11,[14], [15] very closed to that of CQ (log Kaff=10).[18] As clearly evidenced in this report, a stable ternary complex Aβ–Cu–CQ was observed. Contrarily, the much higher affinity of ligand 1 for CuII (log Kaff=16.5)[12] allows to obtain an efficient extraction of copper from Aβ. It should be noted that ternary complexes involving Aβ, ZnII and CQ,[19] or Aβ, FeIII and another metal chelating agent,[20] have been reported.
In conclusion, we have demonstrated that a tetradentate ligand is much more suitable for the extraction of copper(II) from copper-loaded amyloids than a simple bidentate ligand such as CQ. An easy extraction of copper(II) at low amyloid/ligand ratio is essential for AD metal regulators in order to facilitate the re-introduction in copper circulation in the brain.
Experimental Section
Aβ peptides were purchased from Bachem, Switzerland. The content of each peptide flask was dissolved by addition of HEPES buffer 100 mm, pH 7.4 (Aβ1–28) or ultrapure Milli-Q water (Aβ1–16). The concentration of Aβ was then measured by UV-visible spectroscopy (ɛ276 nm (Tyr10)=1410 m−1 cm−1).[14]
UV-visible spectra were recorded on a Biochrom Libra S50 or a Specord 205 spectrophotometer (Analytik Jena, Germany). Fluorescence spectra were recorded on a FLSP920 spectrometer (Edinburgh Instruments Ltd, UK), with bandwidth for excitation and emission=2 nm. The Cu–Aβ complex was first prepared by mixing equimolar amounts of Aβ1–28 and CuCl2 in HEPES buffer 50 mm, pH 7.4. The metalation of Aβ was monitored by the decrease of fluorescence (see Ref. [14]). A solution of ligand 1 or CQ in DMSO was then added (1 or 2 mol equiv, respectively), and the reaction was monitored by UV-visible spectroscopy. Final concentrations were [Aβ1–28]=[Cu2+]=[1]=20 μm, [CQ]=40 μm; DMSO/HEPES buffer=5:95 v/v. The 50 % decrease of fluorescence of Aβ upon metalation by copper was confirmed in buffered mixture containing up to 10 vol % of an organic solvent, namely CH3CN (Ref. [12]), or DMSO (present report, data not shown).
X-Band (9.525 GHz) ESR spectra were recorded in quartz tubes at 120 K, using a Bruker Elexsys-II E500 spectrometer. For experiments with ligand 1, the solvent was HEPES buffer 100 mm, pH 7.4, containing 1–3 vol % of DMSO. [Aβ1–16]=185 μm; Aβ1–16/Cu molar ratio=1:1 (Figure 3 a), Aβ1–16/Cu/1=1:1:0.5 (Figure 3 b), Aβ1–16/Cu/1=1:1:1 (Figure 3 c), Cu/1=1:1 (Figure 3 d). The addition of 1–6 vol % of DMSO in HEPES did not induce modification of the spectrum of Cu–Aβ1–16 (data not shown). For experiments with CQ, the solvent was DMSO/HEPES buffer 100 mm, pH 7.4, 90:10 v/v. [Aβ1−16]=280 μm; Aβ1–16/Cu molar ratio=1:1 (Figure 5 a), Aβ1–16/Cu/CQ=1:1:1 (Figure 5 b), Aβ1−16/Cu/CQ=1:1:2 (Figure 5 c), Cu/CQ=1:2 (Figure 5 d).
ESI-MS analyses were performed on a Waters Xevo-G2QTOF mass spectrometer. The sample solutions were injected (7.5 μL) using a mobile phase CH3OH/H2O (90:10 v/v), flow rate=0.15 mL min−1. The cone voltage was 15 V, and spectra were acquired in the positive ion mode, in the m/z range 100–2500. The mixture of Aβ1–16/CuCl2/CQ (1:1:1 mol ratio) was prepared in ultrapure Milli-Q water (pH 5.8)/MeOH (1:1 v/v). Final concentration was 100 μm, injected volume was 7.5 μL. The series of multicharged patterns at m/z=1161.9, 774.9, and 581.4 was not detected in the absence of Cu2+.
Acknowledgments
This work was supported by the French National Centre for Scientific Research (CNRS).
Supporting Information
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Supplementary
References
- 1.Maurer K, Volk S, Gerbaldo H. Lancet. 1997;349:1546–1549. doi: 10.1016/S0140-6736(96)10203-8. [DOI] [PubMed] [Google Scholar]
- 2.Hershey CO, Hershey LA, Varnes A, Vibhakar SD, Lavin P, Strain WH. Neurology. 1983;33:1350–1353. doi: 10.1212/wnl.33.10.1350. [DOI] [PubMed] [Google Scholar]
- 3.Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. J. Neurol. Sci. 1998;158:47–52. doi: 10.1016/s0022-510x(98)00092-6. [DOI] [PubMed] [Google Scholar]
- 4.Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. J. Biol. Chem. 1998;273:12817–12826. doi: 10.1074/jbc.273.21.12817. [DOI] [PubMed] [Google Scholar]
- 5.Telpoukhovskaia MA, Orvig C. Chem. Soc. Rev. 2013;42:1836–1846. doi: 10.1039/c2cs35236b. [DOI] [PubMed] [Google Scholar]
- 6.Gabbita SP, Lovell MA, Markesbery WR. J. Neurochem. 1998;71:2034–2040. doi: 10.1046/j.1471-4159.1998.71052034.x. [DOI] [PubMed] [Google Scholar]
- 7.Citron M. Nat. Rev. Drug Discovery. 2010;9:387–398. doi: 10.1038/nrd2896. [DOI] [PubMed] [Google Scholar]
- 8.Patten DA, Germain M, Kelly MA, Slack RS. J. Alzheimer′s Dis. 2010;20:357–367. doi: 10.3233/JAD-2010-100498. , S. [DOI] [PubMed] [Google Scholar]
- 9.Faller P, Hureau C. Chem. Eur. J. 2012;18:15910–15920. doi: 10.1002/chem.201202697. [DOI] [PubMed] [Google Scholar]
- 10.Cassagnes LE, Hervé V, Nepveu F, Hureau C, Faller P, Collin F. Angew. Chem. Int. Ed. 52:11110–11113. doi: 10.1002/anie.201305372. [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2013;125 [Google Scholar]
- 11.Ceccom J, Coslédan F, Halley H, Francès B, Lassalle JM, Meunier B. PLoS One. 2012;7:43105. doi: 10.1371/journal.pone.0043105. , e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Nguyen M. Robert A. Sournia-Saquet A. Vendier L. Meunier B. Chem. Eur. J. 2014;20:6771–6785. doi: 10.1002/chem.201402143. b) See p. 6781 and Figure S1 in Ref. [12a]. [DOI] [PubMed] [Google Scholar]
- 13.Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Neuron. 2001;30:665–676. doi: 10.1016/s0896-6273(01)00317-8. [DOI] [PubMed] [Google Scholar]
- 14.Alies B, Renaglia E, Rózga M, Bal W, Faller P, Hureau C. Anal. Chem. 2013;85:1501–1508. doi: 10.1021/ac302629u. [DOI] [PubMed] [Google Scholar]
- 15.Sarell CJ, Syme CD, Rigby SEJ, Viles JH. Biochemistry. 2009;48:4388–4402. doi: 10.1021/bi900254n. [DOI] [PubMed] [Google Scholar]
- 16.Dorlet P, Gambarelli S, Faller P, Hureau C. Angew. Chem. Int. Ed. 48:9273–9276. doi: 10.1002/anie.200904567. [DOI] [PubMed] [Google Scholar]; Angew. Chem. 2009;121 [Google Scholar]
- 17.Kenche VB, Zawisza I, Masters CL, Bal W, Barnham KJ, Drew SC. Inorg. Chem. 2013;52:4303–4318. doi: 10.1021/ic302289r. [DOI] [PubMed] [Google Scholar]
- 18.Ferrada E, Arancibia V, Loeb B, Norambuena E, Olea-Azar C, Huidobro-Toro JP. Neurotoxicology. 2007;28:445–449. doi: 10.1016/j.neuro.2007.02.004. [DOI] [PubMed] [Google Scholar]
- 19.Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI. Aging Cell. 2006;5:69–79. doi: 10.1111/j.1474-9726.2006.00196.x. [DOI] [PubMed] [Google Scholar]
- 20.Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Zhou F. Biochemistry. 2009;48:7939–7947. doi: 10.1021/bi900907a. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Supplementary
